CAS: 827-24-7; 2-Bromo-4-Methyl-6-Nitroaniline

该化合物是一种卤化硝酸性衍生物,其分子式为C7H7BRN2O2,该化合物是有机合成的多用途中间体,特别是在染料,药品和农用化学制品的制作方面;溴和硝基化合物的存在增强了其反应性,使得其在电益和核生殖替代反应中能够选择性地发挥功能;其晶体形式确保实验室环境的稳定性和处理便利性;该化合物的清晰结构和纯度使其适合于需要精确分子修改的研究应用;在处理过程中,由于对光和热的潜在敏感性,应当谨慎行事;建议在惰性条件下适当储存,以保持其完整性.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

乙酸-(2-溴-4-甲基-6-硝基-苯胺) Acetic Acid-(2-Bromo-4-Methyl-6-Nitro-Anilide) 70733-24-3
4-甲基-2-硝基苯胺 4-Methyl-2-Nitroaniline 89-62-3

合成工艺路线路线简述

  • 合成目标产物 2-Bromo-4-Methyl-6-Nitroaniline 主要起始原料 4-Methyl-2-Nitroaniline
  • (文献来源)合成步骤主要原料 4-Methyl-2-Nitroaniline
📜2'-溴-4'-甲基乙酰苯胺置于硝酸体系中,化学反应生成 2-溴-4-甲基-6-硝基苯胺
参考文献:Wroblewski,Justus Liebigs Annalen Der Chemie,1878,Vol. 192,P. 203
标题:Wroblewski,Justus Liebigs Annalen Der Chemie,1878,Vol. 192,P. 203

海关参考信息

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献


参考文献:10.1126/science.abo7201
摘要:Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC; COVID Moonshot Consortium‡, Chodera JD, Lee AA, London N, von Delft A, von Delft F, Achdout H, Aimon A, Alonzi DS, Arbon R, Aschenbrenner JC, Balcomb BH, Bar-David E, Barr H, Ben-Shmuel A, Bennett J, Bilenko VA, Borden B, Boulet P, Bowman GR, Brewitz L, Brun J, Bvnbs S, Calmiano M, Carbery A, Carney DW, Cattermole E, Chang E, Chernyshenko E, Clyde A, Coffland JE, Cohen G, Cole JC, Contini A, Cox L, Croll TI, Cvitkovic M, De Jonghe S, Dias A, Donckers K, Dotson DL, Douangamath A, Duberstein S, Dudgeon T, Dunnett LE, Eastman P, Erez N, Eyermann CJ, Fairhead M, Fate G, Fedorov O, Fernandes RS, Ferrins L, Foster R, Foster H, Fraisse L, Gabizon R, García-Sastre A, Gawriljuk VO, Gehrtz P, Gileadi C, Giroud C, Glass WG, Glen RC, Glinert I, Godoy AS, Gorichko M, Gorrie-Stone T, Griffen EJ, Haneef A, Hassell Hart S, Heer J, Henry M, Hill M, Horrell S, Huang QYJ, Huliak VD, Hurley MFD, Israely T, Jajack A, Jansen J, Jnoff E, Jochmans D, John T, Kaminow B, Kang L, Kantsadi AL, Kenny PW, Kiappes JL, Kinakh SO, Kovar B, Krojer T, La VNT, Laghnimi-Hahn S, Lefker BA, Levy H, Lithgo RM, Logvinenko IG, Lukacik P, Macdonald HB, MacLean EM, Makower LL, Malla TR, Marples PG, Matviiuk T, McCorkindale W, McGovern BL, Melamed S, Melnykov KP, Michurin O, Miesen P, Mikolajek H, Milne BF, Minh D, Morris A, Morris GM, Morwitzer MJ, Moustakas D, Mowbray CE, Nakamura AM, Neto JB, Neyts J, Nguyen L, Noske GD, Oleinikovas V, Oliva G, Overheul GJ, Owen CD, Pai R, Pan J, Paran N, Payne AM, Perry B, Pingle M, Pinjari J, Politi B, Powell A, Pšenák V, Pulido I, Puni R, Rangel VL, Reddi RN, Rees P, Reid SP, Reid L, Resnick E, Ripka EG, Robinson RP, Rodriguez-Guerra J, Rosales R, Rufa DA, Saar K, Saikatendu KS, Salah E, Schaller D, Scheen J, Schiffer CA, Schofield CJ, Shafeev M, Shaikh A, Shaqra AM, Shi J, Shurrush K, Singh S, Sittner A, Sjö P, Skyner R, Smalley A, Smeets B, Smilova MD, Solmesky LJ, Spencer J, Strain-Damerell C, Swamy V, Tamir H, Taylor JC, Tennant RE, Thompson W, Thompson A, Tomásio S, Tomlinson CWE, Tsurupa IS, Tumber A, Vakonakis I, van Rij RP, Vangeel L, Varghese FS, Vaschetto M, Vitner EB, Voelz V, Volkamer A, Walsh MA, Ward W, Weatherall C, Weiss S, White KM, Wild CF, Witt KD, Wittmann M, Wright N, Yahalom-Ronen Y, Yilmaz NK, Zaidmann D, Zhang I, Zidane H, Zitzmann N, Zvornicanin SN. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science. 2023 Nov 10;382(6671):eabo7201.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知